Site-selective protein-modification chemistry for basic biology and drug development

Nature Chemistry

Volumn 8, Issue 2, 2016, Pages 103-113

  Krall, Nikolaus ^a   Da Cruz, Filipa P ^b   Boutureira, Omar ^c   Bernardes, Gonçalo J L ^b,c  

^a ETH ZURICH   (Switzerland)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

CHEMISTRY; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

DRUG DISCOVERY; HUMANS; PROTEINS;

EID: 84955479211     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.2393     Document Type: Review

References (75)

1. Walsh, C. T., Garneau-Tsodikova, S. & Gatto, G. J. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed. 44, 7342-7372 (2005).
2. Stephanopoulos, N. & Francis, M. B. Choosing an effective protein bioconjugation strategy. Nature Chem. Biol. 7, 876-884 (2011).
3. Chalker, J. M., Bernardes, G. J. L., Lin, Y. A. & Davis, B. G. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem. Asian J. 4, 630-640 (2009).
4. Gaertner, H. F. & Offord, R. E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chem. 7, 38-44 (1996).
5. Dawson, P., Muir, T., Clark-Lewis, I. & Kent, S. Synthesis of proteins by native chemical ligation. Science 266, 776-779 (1994).
6. Xie, J. & Schultz, P. G. A chemical toolkit for proteins - an expanded genetic code. Nature Rev. Mol. Cell Biol. 7, 775-782 (2006).
7. Davis, L. & Chin, J. W. Designer proteins: applications of genetic code expansion in cell biology. Nature Rev. Mol. Cell Biol. 13, 168-182 (2012).
8. Lang, K. & Chin, J. W. Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins. Chem. Rev. 114, 4764-4806 (2014).
9. Sletten, E. M. & Bertozzi, C. R. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angew. Chem. Int. Ed. 48, 6974-6998 (2009).
10. Elliott, T. S. et al. Proteome labeling and protein identification in specific tissues and at specific developmental stages in an animal. Nature Biotech. 32, 465-472 (2014).
11. Schumacher, D. & Hackenberger, C. P. R. More than add-on: chemoselective reactions for the synthesis of functional peptides and proteins. Curr. Opin. Chem. Biol. 22, 62-69 (2014).
12. Spicer, C. D. & Davis, B. G. Selective chemical protein modification. Nature Commun. 5, 4740 (2014).
13. Arur, S. & Schedl, T. Generation and purification of highly specific antibodies for detecting post-translationally modified proteins in vivo. Nature Protoc. 9, 375-395 (2014).
14. Burckstummer, T. et al. An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nature Methods 3, 1013-1019 (2006).
15. Wang, P. et al. Erythropoietin derived by chemical synthesis. Science 342, 1357-1360 (2013).
16. Muir, T. W., Sondhi, D. & Cole, P. A. Expressed protein ligation: a general method for protein engineering. Proc. Natl Acad. Sci. USA 95, 6705-6710 (1998).
17. Fierz, B. & Muir, T. W. Chromatin as an expansive canvas for chemical biology. Nature Chem. Biol. 8, 417-427 (2012).
18. Casadio, F. et al. H3R42me2a is a histone modification with positive transcriptional effects. Proc. Natl Acad. Sci. USA 110, 14894-14899 (2013).
19. Kee, J.-M., Oslund, R. C., Perlman, D. H. & Muir, T. W. A pan-specific antibody for direct detection of protein histidine phosphorylation. Nature Chem. Biol. 9, 416-421 (2013).
20. Chalker, J. M. et al. Methods for converting cysteine to dehydroalanine on peptides and proteins. Chem. Sci. 2, 1666-1676 (2011).
21. Chooi, K. P. et al. Synthetic phosphorylation of p38α recapitulates protein kinase activity. J. Am. Chem. Soc. 136, 1698-1701 (2014).
22. Serwa, R. et al. Chemoselective Staudinger-phosphite reaction of azides for the phosphorylation of proteins. Angew. Chem. Int. Ed. 48, 8234-8239 (2009).
23. Chalker, J. M., Lercher, L., Rose, N. R., Schofield, C. J. & Davis, B. G. Conversion of cysteine into dehydroalanine enables access to synthetic histones bearing diverse post-translational modifications. Angew. Chem. Int. Ed. 51, 1835-1839 (2012).
24. Simon, M. D. et al. The site-specific installation of methyl-lysine analogs into recombinant histones. Cell 128, 1003-1012 (2007).
25. Huang, R. et al. Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylation. J. Am. Chem. Soc. 132, 9986-9987 (2010).
26. Chatterjee, C., McGinty, R. K., Fierz, B. & Muir, T. W. Disulfide-directed histone ubiquitylation reveals plasticity in hDot1L activation. Nature Chem. Biol. 6, 267-269 (2010).
27. Li, F. et al. A direct method for site-specific protein acetylation. Angew. Chem. Int. Ed. 50, 9611-9614 (2011).
28. Virdee, S. et al. Traceless and site-specific ubiquitination of recombinant proteins. J. Am. Chem. Soc. 133, 10708-10711 (2011).
29. Virdee, S., Ye, Y., Nguyen, D. P., Komander, D. & Chin, J. W. Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. Nature Chem. Biol. 6, 750-757 (2010).
30. Madrzak, J. et al. Ubiquitination of the dishevelled DIX domain blocks its head-to-tail polymerization. Nature Commun. 6, 6718 (2015).
31. Schneider, T. et al. Dissecting ubiquitin signaling with linkage-defined and protease resistant ubiquitin chains. Angew. Chem. Int. Ed. 53, 12925-12929 (2014).
32. Hemantha, H. P. et al. Nonenzymatic polyubiquitination of expressed proteins. J. Am. Chem. Soc. 136, 2665-2673 (2014).
33. van Kasteren, S. I. et al. Expanding the diversity of chemical protein modification allows post-translational mimicry. Nature 446, 1105-1109 (2007).
34. Neumann, H. et al. A method for genetically installing site-specific acetylation in recombinant histones defines the effects of H3 K56 acetylation. Mol. Cell 36, 153-163 (2009).
35. Perols, A. et al. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules. Bioconjugate Chem. 23, 1661-1670 (2012).
36. Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotech. 26, 925-932 (2008).
37. Sachdeva, A., Wang, K., Elliott, T. & Chin, J. W. Concerted, rapid, quantitative, and site-specific dual labeling of proteins. J. Am. Chem. Soc. 136, 7785-7788 (2014).
38. Tyagi, S. & Lemke, E. A. in Methods in Cell Biology, Vol. 113 (ed. Michael Conn, P.) Ch. 9, 169-187 (Academic Press, 2013).
39. Wang, K. et al. Optimized orthogonal translation of unnatural amino acids enables spontaneous protein double-labelling and FRET. Nature Chem. 6, 393-403 (2014).
40. Lang, K. et al. Genetically encoded norbornene directs site-specific cellular protein labelling via a rapid bioorthogonal reaction. Nature Chem. 4, 298-304 (2012).
41. Zheng, S., Zhang, G., Li, J. & Chen, P. R. Monitoring endocytic trafficking of anthrax lethal factor by precise and quantitative protein labeling. Angew. Chem. Int. Ed. 53, 6449-6453 (2014).
42. Zeglis, B. M. et al. A pretargeted pet imaging strategy based on bioorthogonal Diels-Alder click chemistry. J. Nucl. Med. 54, 1389-1396 (2013).
43. Rashidian, M. et al. Use of 18F-2-fluorodeoxyglucose to label antibody fragments for immuno-positron emission tomography of pancreatic cancer. ACS Cent. Sci. 1, 142-147 (2015).
44. Rossin, R., Läppchen, T., van den Bosch, S. M., Laforest, R. & Robillard, M. S. Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody. J. Nucl. Med. 54, 1989-1995 (2013).
45. Seitchik, J. L. et al. Genetically encoded tetrazine amino acid directs rapid site-specific in vivo bioorthogonal ligation with trans-cyclooctenes. J. Am. Chem. Soc. 134, 2898-2901 (2012).
46. Yang, M. et al. Converting a solvatochromic fluorophore into a protein-based pH indicator for extreme acidity. Angew. Chem. Int. Ed. 51, 7674-7679 (2012).
47. Chari, R. V. J., Miller, M. L. & Widdison, W. C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. 53, 3796-3827 (2014).
48. Pasut, G. & Veronese, F. M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 61, 1177-1188 (2009).
49. Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442-1448 (2011).
50. Keefe, A. J. & Jiang, S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nature Chem. 4, 59-63 (2012).
51. Pelegri-O'Day, E. M., Lin, E.-W. & Maynard, H. D. Therapeutic protein-polymer conjugates: advancing beyond pegylation. J. Am. Chem. Soc. 136, 14323-14332 (2014).
52. Gilmore, J. M., Scheck, R. A., Esser-Kahn, A. P., Joshi, N. S. & Francis, M. B. N-terminal protein modification through a biomimetic transamination reaction. Angew. Chem. Int. Ed. 45, 5307-5311 (2006).
53. MacDonald, J. I., Munch, H. K., Moore, T. & Francis, M. B. One-step site-specific modification of native proteins with 2-pyridinecarboxyaldehydes. Nature Chem. Biol. 11, 326-331 (2015).
54. Cho, H. et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108, 9060-9065 (2011).
55. Chari, R. V. J. et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 52, 127-131 (1992).
56. Beckley, N. S., Lazzareschi, K. P., Chih, H.-W., Sharma, V. K. & Flores, H. L. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjugate Chem. 24, 1674-1683 (2013).
57. Hamblett, K. J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004).
58. Shen, B.-Q. et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotech. 30, 184-189 (2012).
59. Steiner, M. et al. Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature. Chem. Sci. 4, 297-302 (2013).
60. Cal, P. M. S. D., Bernardes, G. J. L. & Gois, P. M. P. Cysteine-selective reactions for antibody conjugation. Angew. Chem. Int. Ed. 53, 10585-10587 (2014).
61. Lyon, R. P. et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotech. 32, 1059-1062 (2014).
62. Tumey, L. N. et al. Mild method for succinimide hydrolysis on ADCs: impact on adc potency, stability, exposure, and efficacy. Bioconjugate Chem. 25, 1871-1880 (2014).
63. Toda, N., Asano, S. & Barbas, C. F. Rapid, stable, chemoselective labeling of thiols with Julia-Kocieński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew. Chem. Int. Ed. 52, 12592-12596 (2013).
64. Bernardes, G. J. L., Chalker, J. M., Errey, J. C. & Davis, B. G. Facile conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile and switchable access to functionalized proteins. J. Am. Chem. Soc. 130, 5052-5053 (2008).
65. Axup, J. Y. et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl Acad. Sci. USA 109, 16101-16106 (2012).
66. Tian, F. et al. A general approach to site-specific antibody drug conjugates. Proc. Natl Acad. Sci. USA 111, 1766-1771 (2014).
67. Agarwal, P., van der Weijden, J., Sletten, E. M., Rabuka, D. & Bertozzi, C. R. A Pictet-Spengler ligation for protein chemical modification. Proc. Natl Acad. Sci. USA 110, 46-51 (2013).
68. Drake, P. M. et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjugate Chem. 25, 1331-1341 (2014).
69. Li, J. et al. Palladium-triggered deprotection chemistry for protein activation in living cells. Nature Chem. 6, 352-361 (2014).
70. Li, J., Jia, S. & Chen, P. R. Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells. Nature Chem. Biol. 10, 1003-1005 (2014).
71. Versteegen, R. M., Rossin, R., ten Hoeve, W., Janssen, H. M. & Robillard, M. S. Click to release: instantaneous doxorubicin elimination upon tetrazine ligation. Angew. Chem. Int. Ed. 52, 14112-14116 (2013).
72. Nguyen, D. P. et al. Genetic encoding of photocaged cysteine allows photoactivation of TEV protease in live mammalian cells. J. Am. Chem. Soc. 136, 2240-2243 (2014).
73. Arbely, E., Torres-Kolbus, J., Deiters, A. & Chin, J. W. Photocontrol of tyrosine phosphorylation in mammalian cells via genetic encoding of photocaged tyrosine. J. Am. Chem. Soc. 134, 11912-11915 (2012).
74. Liu, W., Brock, A., Chen, S., Chen, S. & Schultz, P. G. Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nature Methods 4, 239-244 (2007).
75. Goodman, C. Making sense of nonsense. Nature Chem. Biol. 10, 167-167 (2014).